3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide: Unlocking New Dimensions in H+,K+-ATPase Inhibition Research

Introduction

Disorders of gastric acid secretion, such as peptic ulcer disease and gastroesophageal reflux, have long been studied using classical pharmacological probes. However, the advent of highly selective H+,K+-ATPase inhibitors has enabled far more nuanced interrogation of the proton pump inhibition pathway and its systemic consequences. 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide (SKU: A2845) from APExBIO is a next-generation research tool that not only advances gastric acid secretion research but also offers a platform for exploring the broader physiological and pathophysiological roles of acid-base homeostasis, including emerging neurogastroenterological axes. This article presents a systems-level synthesis of current knowledge, highlighting how this compound enables research beyond established paradigms and addresses content gaps in the current literature.

Mechanism of Action and Biochemical Profile

Targeting the H+,K+-ATPase Signaling Pathway

3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide acts as a potent, selective inhibitor of the gastric H+,K+-ATPase—the primary proton pump responsible for the final step of gastric acid secretion. By binding to the catalytic subunit, it effectively blocks the exchange of intracellular H⁺ for extracellular K⁺, reducing acid secretion at its source. The compound exhibits an IC₅₀ of 5.8 μM against H+,K+-ATPase and demonstrates remarkable potency in inhibiting histamine-induced acid formation (IC₅₀ = 0.16 μM), underscoring its value as an antiulcer agent for research and as a reference inhibitor for dissecting the proton pump inhibition pathway.

Chemical and Experimental Attributes

Structurally, the molecule (C₁₇H₁₉N₃O₃S; MW: 345.42) is a solid, highly pure (≥98% by HPLC and NMR), and optimized for reproducible results in laboratory settings. Its solubility profile—insoluble in water and ethanol, but highly soluble in DMSO (≥17.27 mg/mL)—facilitates flexible assay development. For optimal experimental outcomes, storage at –20°C is recommended, and long-term solution storage should be avoided.

Beyond Gastric Acid: Systems Biology and the Gut–Liver–Brain Axis

Expanding the Scope of Antiulcer Activity Study

While prior works have detailed the mechanistic specificity of this compound in gastric acid secretion (see this advanced review), our perspective extends to the broader systems-level implications. Gastric acid secretion inhibitors like A2845 are now being leveraged to build sophisticated peptic ulcer disease models that integrate gut, hepatic, and neural endpoints—an evolution from traditional monodimensional studies.

Insights from Neuroinflammation Research

Recent advances highlight the critical interplay between gastric acid regulation, microbiota composition, and neuroinflammation—a triad central to the gut–liver–brain axis. The seminal study by Kong et al. (European Journal of Neuroscience, 2025) demonstrated the utility of [18F]PBR146 PET imaging to monitor neuroinflammation in rat models of hepatic encephalopathy (HE). The findings revealed that dysbiosis and altered gut permeability—potentially modulated by changes in gastric acid and pH—can affect neuroinflammatory signaling. While the study focused on microbiota-targeted interventions (Bifidobacterium, FMT), it underscores the need for precise pharmacological models to dissect causality within the gut–liver–brain axis. Here, selective H+,K+-ATPase inhibitors like A2845 can provide unmatched control over gastric acid variables, enabling researchers to probe how gastric pH alterations impact systemic inflammation, microbiota profiles, and neurological endpoints.

Comparative Analysis: A2845 Versus Traditional and Next-Generation Inhibitors

Distinguishing Features and Advantages

Compared to widely used agents such as IC omeprazole, A2845 offers:

• Superior Selectivity: Minimal off-target activity in cellular models, enhancing data clarity.
• Consistent Bioactivity: Verified by batch-to-batch HPLC and NMR analyses, ensuring reproducibility.
• Workflow Flexibility: High DMSO solubility supports both in vitro and ex vivo applications.

These features translate into a robust platform for both hypothesis-driven experiments and high-throughput screening, as previously outlined in application-focused reviews (see scenario-driven protocol optimizations). However, this article advances the discussion by focusing on the integration of A2845 into multi-organ and systems-level models, a domain not covered in prior works.

Limitations of Conventional Models

Traditional gastric acid secretion inhibitors, including older proton pump inhibitors (PPIs), often suffer from limited specificity and unpredictable pharmacokinetics in animal models. This can obscure interpretation in studies where cross-talk between gastric, hepatic, and neural tissues is critical. A2845’s high chemical purity and defined solubility enable the dissection of these complex interactions with greater confidence.

Advanced Applications in Gastro-Neuro Research and Beyond

Designing Next-Generation Peptic Ulcer Disease Models

Emerging research seeks to bridge gastric acid secretion research with models of systemic inflammation, neurodegeneration, and hepatic dysfunction. By using 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide as a standardized gastric acid secretion inhibitor, investigators can:

• Precisely modulate gastric pH to study downstream effects on gut microbiota and permeability
• Develop multifactorial models of peptic ulcer disease that incorporate hepatic and neural biomarkers
• Leverage imaging platforms (e.g., PET with [18F]PBR146) to noninvasively monitor neuroinflammation as a function of gastric intervention, as demonstrated in the Kong et al. study

This multi-layered approach enables the exploration of complex interactions within the gut–liver–brain axis, facilitating discoveries beyond classical antiulcer paradigms.

Translational Impact and Future Directions

By integrating selective H+,K+-ATPase inhibitors into advanced animal models, researchers can unravel causal links between gastric acid dynamics, microbiota composition, and neuroinflammatory states. This represents a distinct advance over prior content, which has primarily emphasized either mechanistic insights (focused on selectivity and workflow) or translational guidance within the confines of gastric pathophysiology (see strategic roadmap articles). Our approach highlights the potential for cross-disciplinary research, including immunology and neuroscience, where modulation of gastric acid may influence systemic and neural health outcomes.

Experimental Considerations and Best Practices

Optimizing Assay Design and Data Integrity

For reproducible results, it is crucial to:

• Utilize freshly prepared DMSO stock solutions of A2845, avoiding prolonged solution storage
• Employ appropriate negative and positive controls, such as IC omeprazole, to benchmark activity
• Incorporate multi-organ readouts (e.g., gastric, hepatic, neural) to capture systems-level effects

These guidelines ensure that the unique properties of SKU: A2845 are fully leveraged for high-content, interpretable experiments.

Conclusion and Future Outlook

3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide (APExBIO, SKU: A2845) has emerged as a transformative H+,K+-ATPase inhibitor for advanced gastric acid secretion and antiulcer activity studies. Its unique selectivity, chemical purity, and solubility profile make it an indispensable tool for dissecting the proton pump inhibition pathway, modeling gastric acid-related disorders, and probing the gut–liver–brain axis in translational research. By enabling controlled, systems-level investigations—including neuroinflammation imaging paradigms as described in the recent neurogastroenterology study—A2845 supports the next generation of scientific discovery. Researchers are encouraged to adopt this compound for both established and innovative study designs, catalyzing advances in gastroenterology, neuroscience, and immunology.

For further technical details and to order, visit the official product page for 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide (SKU: A2845) at APExBIO.